AR026163A1 - Utilizacion de retigabina para el tratamiento de dolores neuropaticos - Google Patents

Utilizacion de retigabina para el tratamiento de dolores neuropaticos

Info

Publication number
AR026163A1
AR026163A1 ARP000105028A ARP000105028A AR026163A1 AR 026163 A1 AR026163 A1 AR 026163A1 AR P000105028 A ARP000105028 A AR P000105028A AR P000105028 A ARP000105028 A AR P000105028A AR 026163 A1 AR026163 A1 AR 026163A1
Authority
AR
Argentina
Prior art keywords
retigabine
treatment
neuropatic pain
pain
neuropatic
Prior art date
Application number
ARP000105028A
Other languages
English (en)
Original Assignee
Asta Medica Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Asta Medica Ag filed Critical Asta Medica Ag
Publication of AR026163A1 publication Critical patent/AR026163A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Emergency Medicine (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La invencionse refiere a la utilizacion de 2-amino-4-(4-fluorobencilamino)-1-etoxicarbonilaminobenceno de la formula I (INN:retigabina) o sus sales de utilizacion farmacéutica para la profilaxis y el tratamiento de dolores neuropáticos.
ARP000105028A 1999-09-27 2000-09-26 Utilizacion de retigabina para el tratamiento de dolores neuropaticos AR026163A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US09/406,135 US6117900A (en) 1999-09-27 1999-09-27 Use of retigabine for the treatment of neuropathic pain

Publications (1)

Publication Number Publication Date
AR026163A1 true AR026163A1 (es) 2003-01-29

Family

ID=23606675

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP000105028A AR026163A1 (es) 1999-09-27 2000-09-26 Utilizacion de retigabina para el tratamiento de dolores neuropaticos

Country Status (35)

Country Link
US (1) US6117900A (es)
EP (1) EP1223927B1 (es)
JP (1) JP2003510273A (es)
KR (1) KR100730829B1 (es)
CN (2) CN100522155C (es)
AR (1) AR026163A1 (es)
AT (1) ATE288748T1 (es)
AU (1) AU777764B2 (es)
BG (1) BG65795B1 (es)
BR (1) BR0014293A (es)
CA (2) CA2659048A1 (es)
CZ (1) CZ295980B6 (es)
DE (1) DE50009504D1 (es)
DK (1) DK1223927T3 (es)
EE (1) EE05073B1 (es)
ES (1) ES2237461T3 (es)
HK (1) HK1052471A1 (es)
HR (1) HRP20020234A2 (es)
HU (1) HUP0202853A3 (es)
IL (3) IL148309A0 (es)
IS (1) IS6303A (es)
MX (1) MXPA02003179A (es)
NO (1) NO329744B1 (es)
NZ (1) NZ517616A (es)
PL (1) PL200847B1 (es)
PT (1) PT1223927E (es)
RS (1) RS50091B (es)
RU (1) RU2264813C2 (es)
SI (1) SI1223927T1 (es)
SK (1) SK286057B6 (es)
TR (1) TR200200706T2 (es)
TW (1) TWI257304B (es)
UA (1) UA72550C2 (es)
WO (1) WO2001022953A2 (es)
ZA (1) ZA200202449B (es)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2411564A1 (en) * 2000-06-09 2001-12-13 The Regents Of The University Of California Method of treating pain using nalbuphine and opioid antagonists
TWI287984B (en) 2000-10-17 2007-10-11 Wyeth Corp Pharmaceutical composition for modulating bladder function
US6589986B2 (en) * 2000-12-20 2003-07-08 Wyeth Methods of treating anxiety disorders
WO2002061075A1 (fr) * 2001-02-01 2002-08-08 Takeda Chemical Industries, Ltd. Proteine de recepteur couple aux proteines g et adn correspondant
IL157313A0 (en) 2001-02-20 2004-02-19 Bristol Myers Squibb Co Modulators of kcnq potassium channels and uses thereof
WO2002080898A2 (en) * 2001-04-04 2002-10-17 Wyeth Methods for treating hyperactive gastric motility
AU2003268424A1 (en) * 2002-09-05 2004-03-29 Scios Inc. Treatment of pain by inhibition of p38 map kinase
US20080039461A1 (en) * 2002-09-05 2008-02-14 Protter Andrew A Treatment of pain by inhibition of p38 map kinase
US7632866B2 (en) 2002-10-21 2009-12-15 Ramot At Tel Aviv University Derivatives of N-phenylanthranilic acid and 2-benzimidazolone as potassium channel and/or neuron activity modulators
AU2003296954A1 (en) * 2002-12-13 2004-07-09 The Regents Of The University Of California Analgesic combination comprising nalbuphine
US7368472B2 (en) * 2002-12-27 2008-05-06 H. Lundbeck A/S 1,2,4-Triaminobenzene derivatives useful for treating disorders of the central nervous system
CN100448867C (zh) * 2002-12-27 2009-01-07 H·隆德贝克有限公司 用于治疗中枢神经系统疾病的1,2,4-三氨基苯衍生物
WO2004096767A1 (en) * 2003-04-25 2004-11-11 H. Lundbeck A/S Sustituted indoline and indole derivatives
US7799832B2 (en) * 2003-10-23 2010-09-21 Valeant Pharmaceuticals North America Combinations of retigabine and sodium channel inhibitors or sodium channel-influencing active compounds for treating pains
TWI349666B (en) 2004-03-12 2011-10-01 Lundbeck & Co As H Substituted morpholine and thiomorpholine derivatives
US7812020B2 (en) 2005-03-03 2010-10-12 H. Lundbeck A/S Substituted pyridine derivatives
US7960436B2 (en) * 2006-06-05 2011-06-14 Valeant Pharmaceuticals International Substituted arylamino-1,2,3,4-tetrahydro naphthalenes and-2,3-dihydro-1H-indenes as potassium channel modulators
US20080045534A1 (en) * 2006-08-18 2008-02-21 Valeant Pharmaceuticals North America Derivatives of 1,3-diamino benzene as potassium channel modulators
NZ575652A (en) * 2006-08-23 2011-08-26 Valeant Pharmaceuticals Int Derivatives of 4-(n-azacycloalkyl) anilides as potassium channel modulators
US8993593B2 (en) * 2006-08-23 2015-03-31 Valeant Pharmaceuticals International N-(4-(6-fluoro-3,4-dihydroisoquinolin-2(1H)-yl)-2,6-dimethylphenyl)-3,3-dimethylbutanamide as potassium channel modulators
US8722929B2 (en) * 2006-10-10 2014-05-13 Valeant Pharmaceuticals International N-[2-amino-4-(phenylmethoxy)phenyl] amides and related compounds as potassium channel modulators
BRPI0719590A2 (pt) * 2006-11-28 2014-01-21 Valeant Pharmaceuticals Int Análogos de retigabina 1,4 diamino bicíclica como modulares de canal de potássio
US8367684B2 (en) * 2007-06-13 2013-02-05 Valeant Pharmaceuticals International Derivatives of 4-(N-azacycloalkyl) anilides as potassium channel modulators
US8563566B2 (en) * 2007-08-01 2013-10-22 Valeant Pharmaceuticals International Naphthyridine derivatives as potassium channel modulators
US7786146B2 (en) * 2007-08-13 2010-08-31 Valeant Pharmaceuticals International Derivatives of 5-amino-4,6-disubstituted indole and 5-amino-4,6-disubstituted indoline as potassium channel modulators
EP2203411B1 (en) 2007-09-20 2016-01-06 Ramot at Tel-Aviv University Ltd. N-phenyl anthranilic acid derivatives and uses thereof
US20100323015A1 (en) * 2008-07-18 2010-12-23 Biljana Nadjsombati Modified release formulation and methods of use
NZ590885A (en) * 2008-07-18 2013-01-25 Valeant Pharmaceuticals Int A modified release pharmaceutical formulation of retigabine for the treatment of nervous system hyperexcitability
US20100323016A1 (en) * 2008-07-18 2010-12-23 Biljana Nadjsombati Modified release formulation and methods of use
DE102009013611A1 (de) 2009-03-17 2010-09-23 Ratiopharm Gmbh Festes Retigabin in nicht-kristalliner Form
DE102009013612A1 (de) 2009-03-17 2010-09-23 Ratiopharm Gmbh Retigabin-Tabletten, bevorzugt mit modifizierter Freisetzung
DE102009013613A1 (de) 2009-03-17 2010-09-23 Ratiopharm Gmbh Trockenverarbeitung von Retigabin
IT1398282B1 (it) * 2009-07-30 2013-02-22 Difass S A Ora Farmapros S P A Composizione comprendente acido alfa-lipoico e carnosina per il trattamento della sindrome dell arto fantasma
US20110087650A1 (en) * 2009-10-06 2011-04-14 Johnson Controls Technology Company Creation and use of causal relationship models in building management systems and applications
TR201002473A2 (tr) * 2010-03-31 2011-09-21 Mustafa Nevzat �La� Sanay�� A.�. Herpes zoster hastalığının bır opiat reseptör antagonist kullanılarak tedavi yöntemi.
RU2446795C1 (ru) * 2011-03-31 2012-04-10 Федеральное государственное учреждение "Московский научно-исследовательский онкологический институт им. П.А. Герцена Министерства здравоохранения и социального развития Российской Федерации" ФГУ "МНИОИ им. П.А. Герцена "Минздравсоцразвития России" Способ предотвращения фантомного болевого синдрома после ампутации конечностей
CN102531966B (zh) * 2011-12-23 2013-07-24 山东创新药物研发有限公司 瑞替加滨的晶型d及其制备方法
US9345689B2 (en) * 2012-05-18 2016-05-24 Gruenenthal Gmbh Pharmaceutical composition comprising (1r,4r)-6′-fluoro-N, N-dimethyl-4-phenyl-4,9′-dihydro-3′H-spiro[cyclohexane-1,1′-pyrano[3,4,b]indol]-4-amine and an anticonvulsant
US9320725B2 (en) 2012-05-18 2016-04-26 Gruenenthal Gmbh Pharmaceutical composition comprising (1r,4r)-6′-fluoro-N,N-dimethyl-4-phenyl-4′9′-dihydro-3′H-spiro[cyclohexane-1,1′-pyrano[3,4,b]indol]-4-amine and a gabapentinoid
US20130310385A1 (en) 2012-05-18 2013-11-21 Gruenenthal Gmbh Pharmaceutical Composition Comprising (1r,4r)-6'-fluoro-N,N-dimethyl-4-phenyl-4',9'-dihydro-3'H-spiro[cyclohexane-1,1'-pyrano[3,4,b]indol]-4-amine and Antidepressants
CN103271899A (zh) * 2012-12-30 2013-09-04 北京阜康仁生物制药科技有限公司 瑞替加滨粉碎粒度在制剂中的应用
CN105919990A (zh) * 2016-06-29 2016-09-07 青岛云天生物技术有限公司 用于预防和治疗神经病理性疼痛的药物组合物及其用途
CN106176715A (zh) * 2016-06-29 2016-12-07 青岛云天生物技术有限公司 一种神经病理性疼痛治疗用药物组合物及其用途
WO2019014547A1 (en) 2017-07-14 2019-01-17 Texas Tech University System FUNCTIONALIZED PYRIDINE CARBAMATES HAVING ENHANCED NEUROPROTECTOR ACTIVITY

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4200259A1 (de) * 1992-01-08 1993-07-15 Asta Medica Ag Neue 1,2,4-triaminobenzol-derivate und verfahren zu deren herstellung
DE19539861A1 (de) * 1995-10-26 1997-04-30 Asta Medica Ag Verwendung von 4-Amino-4-(4-fluorbenzylamino)-1-ethoxy-carbonylaminobenzen zur Prophylaxe und Behandlung der Folgen der akuten und chronischen zerebralen Minderdurchblutung sowie neurodegenerativer Erkrankungen
GB9915414D0 (en) * 1999-07-01 1999-09-01 Glaxo Group Ltd Medical use

Also Published As

Publication number Publication date
PL353393A1 (en) 2003-11-17
DK1223927T3 (da) 2005-04-11
NO20021418L (no) 2002-03-21
ATE288748T1 (de) 2005-02-15
SK286057B6 (sk) 2008-02-05
WO2001022953A2 (de) 2001-04-05
EP1223927A2 (de) 2002-07-24
AU7906100A (en) 2001-04-30
IL148309A0 (en) 2002-09-12
HUP0202853A3 (en) 2003-10-28
BR0014293A (pt) 2002-05-21
IL187030A0 (en) 2008-02-09
DE50009504D1 (de) 2005-03-17
CN100522155C (zh) 2009-08-05
IL148309A (en) 2007-12-03
WO2001022953A3 (de) 2002-05-23
ES2237461T3 (es) 2005-08-01
HUP0202853A2 (hu) 2002-12-28
RU2264813C2 (ru) 2005-11-27
TR200200706T2 (tr) 2002-10-21
SK2922002A3 (en) 2002-08-06
MXPA02003179A (es) 2003-08-20
HRP20020234A2 (en) 2003-06-30
YU20302A (sh) 2005-03-15
CA2384504C (en) 2009-05-26
AU777764B2 (en) 2004-10-28
SI1223927T1 (es) 2005-08-31
EE200200145A (et) 2003-04-15
HK1052471A1 (zh) 2003-09-19
RU2002109240A (ru) 2004-01-10
US6117900A (en) 2000-09-12
RS50091B (sr) 2009-01-22
NZ517616A (en) 2002-12-20
CZ295980B6 (cs) 2005-12-14
BG65795B1 (bg) 2009-12-31
CA2659048A1 (en) 2001-04-05
KR100730829B1 (ko) 2007-06-20
NO20021418D0 (no) 2002-03-21
CA2384504A1 (en) 2001-04-05
CN101444498A (zh) 2009-06-03
PT1223927E (pt) 2005-06-30
EE05073B1 (et) 2008-10-15
CZ2002989A3 (cs) 2002-08-14
JP2003510273A (ja) 2003-03-18
BG106450A (en) 2002-09-30
TWI257304B (en) 2006-07-01
UA72550C2 (en) 2005-03-15
IL187030A (en) 2011-06-30
KR20020042691A (ko) 2002-06-05
IS6303A (is) 2002-03-18
NO329744B1 (no) 2010-12-13
PL200847B1 (pl) 2009-02-27
ZA200202449B (en) 2003-03-26
CN1409632A (zh) 2003-04-09
EP1223927B1 (de) 2005-02-09

Similar Documents

Publication Publication Date Title
AR026163A1 (es) Utilizacion de retigabina para el tratamiento de dolores neuropaticos
BRPI0411900A (pt) compostos antivirais e métodos
BRPI0412763A (pt) formas anidras, hidratadas ou solvatadas de um composto, forma cristalina, composição farmacêutica, e, método para o tratamento ou a profilaxia de distúrbios
RS52625B (en) FLUORO SUBSTITUTED OMEGA-CARBOXYARYL DIPHENYL UREA FOR TREATMENT AND PREVENTION OF DISEASES AND DISEASES
UY24949A1 (es) Compuestos calcilíticos
ES2193337T3 (es) Utilizacion de sales de estroncio para el tratamiento de la artrosis.
PT1259512E (pt) Compostos de pteridin para o tratamento da psoriase
BR9805544A (pt) Uso de um composto.
BR0305258A (pt) Inibidores de polimerase de ns5b de hcv
BRPI0417101A (pt) uso de compostos de peptìdeo para tratamento de dor neuropática central
PT1392292E (pt) Piranoindazoles e sua utilizacao para o tratamento de glaucoma
EA200600971A1 (ru) Применение замещённых 2 - аминотетралинов для профилактического лечения болезни паркинсона
HN2002000110A (es) Uso de (z) - 2 - ciano - 3 - hidroxi - butil - 2 - acido enoico (4' - trifluorometil fenilo) - amida para el tratamiento de la esclerosis multiple.
ES2421948T3 (es) Compuestos y composiciones para suministrar agentes activos
PT1411926E (pt) Inibidores de integrina para o tratamento de doencas oftalmicas
BRPI0508807A (pt) composição de tratamento capilar, uso de uma composição e método de tratamento de cabelo
CL2007002387A1 (es) Uso de compuestos derivados de 2,5-dihidroxibenceno para el tratamiento de artritis y dolor.
CY1109975T1 (el) Παρα-αλκυλ-υποκατεστημενα αμιδια ν-(4-υδροξυ-3-μεθοξυ-βενζυλο) κιναμμωμικου οξεος και η χρησιμοποιηση τους για την παρασκευη φαρμακων
SV2003000741A (es) Compuesto lactamico x-13170
ES2422081T3 (es) Péptido Ser-Ser-Ser-Arg y sus utilizaciones medicinales
BR0215067A (pt) Piridoquinoxalinas antivirais
SE0101082D0 (sv) Novel use
BR9909870A (pt) Pirrolidinas como inibidores de neuraminidases
ITMI20022394A1 (it) Uso di triiodotironina 3-solfato come farmaco ad attivita' tireomimetica e relative formulazioni farmaceutiche.
ECSP056174A (es) Acidos hidroxamicos utiles en el tratamiento detrastornos hiperproliferativos

Legal Events

Date Code Title Description
FB Suspension of granting procedure